Bank of New York Mellon Corp Grows Stake in Savara Inc (NASDAQ:SVRA)

Bank of New York Mellon Corp grew its stake in shares of Savara Inc (NASDAQ:SVRA) by 7.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 253,630 shares of the company’s stock after acquiring an additional 17,870 shares during the period. Bank of New York Mellon Corp’s holdings in Savara were worth $779,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vestal Point Capital LP grew its holdings in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after purchasing an additional 1,600,000 shares during the period. Geode Capital Management LLC lifted its position in shares of Savara by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock valued at $11,564,000 after buying an additional 264,825 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Savara by 238.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock worth $3,865,000 after acquiring an additional 642,259 shares during the period. Barclays PLC increased its holdings in Savara by 217.5% in the 3rd quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after acquiring an additional 158,244 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock valued at $158,000 after acquiring an additional 6,330 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Down 2.1 %

SVRA stock opened at $2.77 on Wednesday. The stock has a 50-day simple moving average of $2.73 and a two-hundred day simple moving average of $3.28. Savara Inc has a twelve month low of $2.26 and a twelve month high of $5.34. The firm has a market capitalization of $475.38 million, a PE ratio of -6.44 and a beta of 0.60. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Analysts Set New Price Targets

A number of equities analysts have weighed in on SVRA shares. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company assumed coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.